EXAS Research and Charts

EXAS - Exact Sciences Corp (Healthcare: Diagnostics & Research)

Projected Earnings Date: 2025-07-31 (Delayed quote data 2025-07-11)

Last 51.91	Change ⇓ -1.41 (-2.64%)	Volume 1,740,471
	Open 53.05	High 53.78	Low 51.76

8EMA (Daily) 53.24	40EMA (Daily) 53.10	50EMA (Daily) 52.82	STO (Daily) 44.077	MACD Hist (Daily) -0.160
8EMA (Weekly) 52.930	40EMA (Weekly) 53.41	50EMA (Weekly) 54.19	STO (Weekly) 70.815	MACD Hist (Weekly) 0.959


Company Profile
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact?s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.